Rapt Therapeutics Stock Debt To Equity

RAPT Stock  USD 1.09  0.08  6.84%   
RAPT Therapeutics fundamentals help investors to digest information that contributes to RAPT Therapeutics' financial success or failures. It also enables traders to predict the movement of RAPT Stock. The fundamental analysis module provides a way to measure RAPT Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to RAPT Therapeutics stock.
Last ReportedProjected for Next Year
Debt To Equity 0.04  0.04 
Debt To Equity is likely to drop to 0.04 in 2025.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

RAPT Therapeutics Company Debt To Equity Analysis

RAPT Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

 = 

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current RAPT Therapeutics Debt To Equity

    
  0.04 %  
Most of RAPT Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, RAPT Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

RAPT Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for RAPT Therapeutics is extremely important. It helps to project a fair market value of RAPT Stock properly, considering its historical fundamentals such as Debt To Equity. Since RAPT Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of RAPT Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of RAPT Therapeutics' interrelated accounts and indicators.
0.950.910.51-0.880.720.91-0.730.951.01.00.930.250.91-0.910.160.9-0.8
0.950.890.36-0.870.710.89-0.91.00.950.950.970.520.83-0.830.190.8-0.74
0.910.890.37-0.970.891.0-0.730.890.910.890.920.20.9-0.92-0.020.78-0.91
0.510.360.37-0.330.20.35-0.090.360.520.540.29-0.320.4-0.410.520.49-0.27
-0.88-0.87-0.97-0.33-0.94-0.980.72-0.87-0.88-0.85-0.92-0.22-0.920.930.17-0.710.9
0.720.710.890.2-0.940.91-0.60.710.710.680.80.120.83-0.85-0.370.58-0.93
0.910.891.00.35-0.980.91-0.740.890.910.880.920.210.91-0.93-0.060.78-0.93
-0.73-0.9-0.73-0.090.72-0.6-0.74-0.9-0.73-0.72-0.87-0.81-0.590.61-0.18-0.540.57
0.951.00.890.36-0.870.710.89-0.90.950.950.970.520.83-0.830.190.8-0.74
1.00.950.910.52-0.880.710.91-0.730.951.00.930.250.9-0.90.190.9-0.79
1.00.950.890.54-0.850.680.88-0.720.951.00.910.250.88-0.890.240.92-0.77
0.930.970.920.29-0.920.80.92-0.870.970.930.910.460.91-0.890.030.74-0.82
0.250.520.2-0.32-0.220.120.21-0.810.520.250.250.460.07-0.080.180.1-0.05
0.910.830.90.4-0.920.830.91-0.590.830.90.880.910.07-0.97-0.090.78-0.9
-0.91-0.83-0.92-0.410.93-0.85-0.930.61-0.83-0.9-0.89-0.89-0.08-0.970.02-0.850.94
0.160.19-0.020.520.17-0.37-0.06-0.180.190.190.240.030.18-0.090.020.30.14
0.90.80.780.49-0.710.580.78-0.540.80.90.920.740.10.78-0.850.3-0.76
-0.8-0.74-0.91-0.270.9-0.93-0.930.57-0.74-0.79-0.77-0.82-0.05-0.90.940.14-0.76
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

RAPT Total Stockholder Equity

Total Stockholder Equity

119.03 Million

At this time, RAPT Therapeutics' Total Stockholder Equity is comparatively stable compared to the past year.
According to the company disclosure, RAPT Therapeutics has a Debt To Equity of 0.04%. This is 99.93% lower than that of the Biotechnology sector and 99.79% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.92% higher than that of the company.

RAPT Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RAPT Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of RAPT Therapeutics could also be used in its relative valuation, which is a method of valuing RAPT Therapeutics by comparing valuation metrics of similar companies.
0.040.1890.1610.141100%
RAPT Therapeutics is currently under evaluation in debt to equity category among its peers.

RAPT Fundamentals

Return On Equity-0.8
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-300%-250%-200%-150%-100%-50%
Return On Asset-0.47
Current Valuation61.66 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-20%0%20%40%60%80%
Shares Outstanding132.01 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%
Shares Owned By Insiders0.49 %
Shares Owned By Institutions96.42 %
Number Of Shares Shorted2.81 M
Price To Book1.62 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-350%-300%-250%-200%-150%-100%-50%
Price To Sales411.22 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%250%300%350%
Gross Profit1.53 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-400%-300%-200%-100%0%100%
EBITDA(125.85 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%250%300%350%
Net Income(116.8 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%250%300%
Cash And Equivalents207.34 M
Cash Per Share6.99 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120%40%60%80%100%120%140%
Total Debt6.91 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-30%-25%-20%-15%-10%-5%
Debt To Equity0.04 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-250%-200%-150%-100%-50%
Current Ratio15.97 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-40%-20%0%20%
Book Value Per Share2.74 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-250%-200%-150%-100%-50%
Cash Flow From Operations(97.05 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%250%
Short Ratio3.42 X
Earnings Per Share(2.78) X
Target Price6.0
Number Of Employees70
Beta0.031
Market Capitalization143.89 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-20%0%20%40%60%
Total Asset173.33 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31100%200%300%400%
Retained Earnings(484.68 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31100%200%300%400%
Working Capital139.95 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Current Asset17 K
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31100%200%300%400%
Current Liabilities167 K
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31100%200%300%400%500%600%700%
Net Asset173.33 M

About RAPT Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze RAPT Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RAPT Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RAPT Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.


 
News Freq…Investor S…